Novo Nordisk Just Lost the Obesity Drug Super Bowl

Wall Street's Verdict: Brutal

Investors didn't wait around for nuance. Novo Nordisk's stock cratered roughly 23% on the day of the announcement, dropping to levels not seen since 2021. The next day, shares slid another 2.5% in Copenhagen. At that point, the stock sat about 60% below its peak from the prior year.

Analysts piled on. William Blair's Andy Hsieh called the result "especially disappointing" because CagriSema had been expected to outperform Zepbound, not trail it. Jefferies' Michael Leuchten questioned what role CagriSema would even play going forward, noting it's hard to justify a premium position for a drug that lost the head-to-head. JPMorgan's Chris Schott said the outcome reinforces Zepbound as the market leader.

At least seven analysts cut their price targets or revised their recommendations. When that many people on Wall Street agree about something, pay attention.

The Two-Horse Race Gets Lopsided

The obesity drug market is, for all practical purposes, a duopoly. Novo Nordisk and Eli Lilly together control the vast majority of GLP-1 obesity revenue, and the total market is growing at a staggering pace. Estimates for 2026 range from $25 billion to over $40 billion globally, with projections reaching $100-200 billion by the mid-2030s.

Novo got to the party first with Wegovy's 2021 approval and built an early lead. But Lilly's tirzepatide franchise (Mounjaro for diabetes, Zepbound for obesity) has been gaining ground fast. This head-to-head result doesn't just slow Novo's momentum; it hands Lilly a marketing gift wrapped in Phase 3 data. "Our drug beat theirs" is about as clean a sales pitch as you can get in pharma.

Bernstein's Courtney Breen and Barclays' James Gordon both noted that the data leave Novo with limited pricing leverage. If your next-generation drug can't match the competition, charging more for it becomes a tough sell.

Novo's Plan B (and C, and D)

To Novo's credit, the company isn't putting all its eggs in the CagriSema basket. Its pipeline reads like a chess player thinking several moves ahead.

The most exciting piece is amycretin, a dual GLP-1 and amylin receptor agonist available in both injectable and oral form. Early data has been eye-catching: up to 24.3% weight loss in just 36 weeks with the injectable version, and 13.1% in only 12 weeks with the oral pill. Phase 3 trials are launching in early 2026.

Meanwhile, Novo's oral semaglutide (a pill version of Wegovy, essentially) got FDA approval at the end of 2025 and is rolling out commercially now. It delivered 16.6% weight loss over 64 weeks in its pivotal trial. Not as potent as the injectables, but for the millions of people who hate needles, convenience matters.

And then there's the deeper pipeline: triple agonists licensed from United Laboratories, oral obesity molecules from a deal with Septerna, a $2.1 billion collaboration with Vivtex to turn injectable biologics into pills, and even a CB1 receptor blocker in Phase 1. Novo has also pruned weaker programs to focus resources on the assets most likely to leapfrog the competition.

The Bigger Picture

The CagriSema loss doesn't kill Novo Nordisk. The drug still produced 20-23% weight loss, which is extraordinary by any historical standard. Five years ago, doctors would have celebrated those numbers. And CagriSema clearly beats semaglutide alone, so there's a path to approval as a step-up therapy for patients who need more weight loss than Wegovy delivers.

But the narrative has shifted. Novo entered 2026 hoping to prove it had the best obesity drug on the planet. Instead, it proved that Lilly does. The question now is whether amycretin can change that story, or whether Lilly's own next-generation drugs (including the oral GLP-1 orforglipron, approved by the FDA in April 2026 under the brand name Foundayo) will keep extending the lead.

This is a $30+ billion market growing at 20-30% annually, so there's room for both companies to thrive. But in the obesity drug Super Bowl, only one team gets to hold the trophy. Right now, that team is wearing Lilly's jersey.

Lilly's New Weight-Loss Drug Makes Ozempic Look Like a Warm-Up

Eli Lilly's triple-agonist retatrutide just posted 28% average weight loss in a Phase 3 trial, blowing past every GLP-1 drug on the market. The post-Ozempic era officially has a frontrunner.